Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine
In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for blood components promise to reduce the residual risk of known and emerging infectious agents. The implementation of PI of labile blood components is slowly but steadily increasing. This review discusse...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-12-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fmed.2017.00219/full |